Skip to main content

Drug Interactions between maraviroc and nevirapine

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Minor

nevirapine maraviroc

Applies to: nevirapine and maraviroc

Coadministration with nevirapine does not appear to significantly alter the plasma concentrations of maraviroc. In 12 study subjects, nevirapine (200 mg twice a day plus lamivudine 150 mg twice a day and tenofovir 300 mg once a day) increased the peak plasma concentration (Cmax) of a single 300 mg dose of maraviroc by 54% but did not affect the overall systemic exposure relative to historical data. No dosage adjustment of maraviroc is necessary when coadministered with nevirapine in the absence of concomitant potent CYP450 3A4 inhibitors such as itraconazole, ketoconazole, delavirdine, clarithromycin, telithromycin, nefazodone, or protease inhibitors.

References (1)
  1. (2007) "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group

Drug and food interactions

Minor

maraviroc food

Applies to: maraviroc

Administration with food may reduce the bioavailability of maraviroc. According to the product labeling, coadministration of a 300 mg dose of maraviroc with a high-fat breakfast reduced maraviroc peak plasma concentration (Cmax) and systemic exposure (AUC) by 33% in healthy volunteers. However, no food restrictions were used in the clinical studies that demonstrated the safety and efficacy of maraviroc. Therefore, maraviroc can be taken with or without food at the recommended dosage.

References (1)
  1. (2007) "Product Information. Selzentry (maraviroc)." Pfizer U.S. Pharmaceuticals Group

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer